Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

ata and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world.
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... the second half of this yearBERLIN and TARRYTOWN, N.Y., ... Inc. (Nasdaq: REGN ) today announced that ... VEGF Trap-Eye, an investigational agent for the treatment of ... (CRVO). The companies plan to initiate a Phase 3 ...
... Investing in New Product Presentations for PatientsSAN DIEGO and ... AMLN ) and Eli Lilly and Company (NYSE: ... have agreed in principle to the terms of a ... device. Separately, the companies announced that they have initiated ...
Cached Medicine Technology:Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 2Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 3Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 4Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 6Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 7
(Date:7/12/2014)... recent article released by Seattle's well known plastic surgeon, Dr. ... cosmetic surgical procedures in summer months . , ... to enliven the rainy Pacific Northwest, many people are turning ... work out as much during the winter as they had ... people eager to look their best for their summer vacations, ...
(Date:7/12/2014)... July 12, 2014 Wright & Schulte LLC, ... in Just For Men Lawsuits (case #59776/2014), announces they ... of reports that allege the popular hair dye, Just For ... to their face, neck and other areas. In addition to ... Men chemical burns , the advertisements being run by Wright ...
(Date:7/12/2014)... Floor-grade instrument buyers ... of 5. This above-average score represents favorable conditions ... negotiation power over the three years to 2014. ... the period, surging demand for healthcare services and ... product development, have placed upward pressure on the ...
(Date:7/12/2014)... 12, 2014 The largest pure occupational ... pleased to announce that it will be opening its ... facility will join four Atlanta-based Nova Medical Centers’ locations. ... 3209 Deans Bridge Road, and will be open from ... , “With Nova’s treatment philosophy of rapid return-to-work and ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... cause infections that typically target the digestive tract or bowel; ... could result. Enterococcus also can invade the bloodstream, ... the heart valve. Typically the only people who become ill ... have health issues, such as diabetes or chronic kidney failure. ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Nov. 16 ... at heightened risk for stroke, a new study suggests. ... the Nurses, Health Study and about 28,000 men from the ... 26 years. Over that time, both men and women ...
... found that flu strains migrate back and forth between different ... contrary to the common belief that flu strains from the ... The research appeared online on Nov. 14 in the ... supported in part by the Centers of Excellence for ...
... imaging (MRI) to evaluate cardiovascular risk in World Trade ... of Medicine have found that the responders who experienced ... on September 11, 2001, demonstrate high-risk features of atherosclerosis ... American Heart Association,s Scientific Sessions 2011 in Orlando, Florida. ...
... Medicine have identified hepcidin, a hormone that regulates iron ... treating atherosclerosis. Suppressing hepcidin is a way to ... found in arterial plaques. Reducing iron levels pushes those ... called "reverse cholesterol transport," interfering with atherosclerosis, researchers have ...
... HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay News) -- First ... following the New York City terror attacks on Sept. 11, ... Those Ground Zero workers who got there first may ... who came on the scene after Sept. 13, and may be ...
Cached Medicine News:Health News:Wayne State University to study novel treatment for antibiotic-resistant bacteria 2Health News:Blood Type May Be Associated With Stroke Risk: Study 2Health News:NIH grantees rebut theory that seasonal flu strains originate in tropical regions 2Health News:NIH grantees rebut theory that seasonal flu strains originate in tropical regions 3Health News:WTC workers exposed earlier to dust cloud have higher risk of atherosclerotic lesions 2Health News:Hormone that controls iron levels may be target for atherosclerosis treatment 2Health News:9/11 First Responders May Face Greater Heart Risks 2Health News:9/11 First Responders May Face Greater Heart Risks 3
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... multimode readers offering 96-channel parallel detection of ... and 1,536-well microtiter plates. Compact workstations ... for the transport of microtiter plates with ... day. The need for mechanical switching required ...
Medicine Products: